Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphazyme AS

www.orphazyme.com

Latest From Orphazyme AS

Finance Watch: Biopharma Stocks See Big Post-IPO Jumps

Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.

Financing Business Strategies

Keeping Track: Submissions From Alkermes, Samsung Bioepis; BTDs for Orphazyme and Kiniksa

The latest submission and expedited review program news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Drug Review

Finance Watch: Summer Slowdown Nears Its End With Strategic Shifts And IPO Hopes

Merrimack's wind-down continues with an activist challenge, but investors approved the Vical/Brickell Biotech reverse merger. Also, the past month's IPO slump may reverse course and HiFiBiO's $67m Series C leads recent financings.

Financing Business Strategies

Orphazyme Steams Ahead With Registration in Niemann Pick, Despite Endpoint Misses

Even with numerous endpoint misses, such is the demand for treatment options for the ultra-rare disease Niemann Pick, Orphazyme is pushing forward with its US and European regulatory filings of arimiclomol, which has no approved therapies in the US and one in the EU.

Rare Diseases Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Orphazyme APS
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Orphazyme AS
  • Senior Management
  • Anders Hinsby, PhD, CEO
    Anders Vadsholt, CFO
    Thomas Kirkegaard Jensen, PhD, CSO
    Thomas Blaettler, MD, CMO
    Paul Merrigan, Chief Commercial Officer
  • Contact Info
  • Orphazyme AS
    Phone: 39 17 82 72
    Ole Maaløes Vej 3
    Copenhagen, DK-2200
    Denmark
UsernamePublicRestriction

Register